Back to search
FDAFDA · Food and drugs·Recall number D-0051-2021

Catapres (clonidine hydrochloride, USP) 0.1 mg, tablet, 100-count bottle, Rx only, Dist. by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877, Made in Germany, NDC, 0597-0006-01

Published November 4, 2020 · Recall initiated: October 5, 2020

Summary

FDA records drug Class II recall D-0051-2021, published November 4, 2020 and initiated October 5, 2020. Recalling firm: Boehringer Ingelheim Pharmaceuticals, Inc.; Status: Terminated; Reported quantity: 13,270 bottles/100 tablets each; Lot: Lot # 761544, 859015, EXP Jan 2021, 861346, 956626, EXP Jan 2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

An extraneous peak was observed for dissolution testing.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Boehringer Ingelheim Pharmaceuticals, Inc.
Distributor
Distributed Nationwide in the USA and Puerto Rico
Lot
Lot # 761544, 859015, EXP Jan 2021, 861346, 956626, EXP Jan 2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Catapres (clonidine hydrochloride, USP) 0.1 mg, tablet, 100-count bottle, Rx only, Dist. by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877, Made in Germany, NDC, 0597-0006-01 recalled?

Yes. FDA published recall D-0051-2021 on November 4, 2020. Reported hazard: An extraneous peak was observed for dissolution testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter